New IHC quantification rules and the joint training with other immunohistochemical biomarkers, such as CD3, CD20, CD5, BCL2, BCL6, Ki67, and MUM1, would be valuable to provide more insights into diagnosis and treatment determination of lymphoma patients. The gene discussed is BCL2; the disease is lymphoma.